Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers
D. Voulgarelis, J. V. Forment, A. Herencia Ropero, D. Polychronopoulos, J. Cohen-Setton, A. Bender, V. Serra, M. J. O’Connor, J. W. T. Yates, K. C. Bulusu · 2024
Read Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers by D. Voulgarelis, J. V. Forment, A. Herencia Ropero, D. Polychronopoulos, J. Cohen-Setton, A. Bender, V. Serra, M. J. O’Connor, J. W. T. Yates, K. C. Bulusu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11574300.txt.
Description
Voulgarelis and a team of co-authors model why breast tumors grown in mice from patient tissue vary so much in their response to a targeted drug. The drug blocks a repair pathway cancer cells lean on, and knowing in advance which tumors resist it is a clinical priority.
Their mathematical model folds an inherited resistance level into tumor growth curves, letting software read each graft's resistance from its growth record. Matching those readings against the tumors' gene activity before treatment surfaced dozens of marker genes, several from the very repair system the drug attacks. One gene tied to a cell-cycle checkpoint stood out, suggesting a drug pairing that might break the resistance. The authors pitch the framework as a step toward precision treatment choices.
Catalog record
| CREATOR | D. Voulgarelis, J. V. Forment, A. Herencia Ropero, D. Polychronopoulos, J. Cohen-Setton, A. Bender, V. Serra, M. J. O’Connor, J. W. T. Yates, K. C. Bulusu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 76 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |